When multiple myeloma relapses
RESPOND with a Kyprolis®-based regimen
Kd progression-free survival after one relapse
In the ENDEAVOR trial, median PFS was more than double with Kd vs Vd in patients after one relapse (22.2 months with Kd vs 10.1 months with Vd; descriptive P<0.0001).1
Kyprolis® has a tolerable safety profile in combination with dexamethasone Detailed treatment regimen in the Kd head-to-head phase 3 ENDEAVOR study
Starting a Kyprolis®-based regimen as the 1st treatment after relapse adds at least an additional year of median PFS vs Kd for your patients1
Please read the SmPC for full comprehensive safety information
- Moreau P et al. Leukemia 2016;1(1):1–8.